Cancer, Solid tumor/s
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) | Biliary Tract Cancer | Phase 2/3 | Oct 24, 2026 | — |
| CTX-8371 | Cancer, Solid tumor/s | Phase 1 | Dec 31, 2026 | Mgmt interest |
| CTX-10726 (PD-1 x VEGF-A bispecific antibody) | Solid tumor/s | Phase 1 | Dec 31, 2026 | Mgmt interest |
Upcoming milestones
Company profile
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Biliary Tract Cancer
Data readoutCancer, Solid tumor/s
Data readout